Japanese Cancer Association

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Dr. Carl Barrett Joins Corista as Chief Life Sciences Officer

Retrieved on: 
Tuesday, September 26, 2023

CONCORD, Mass., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Dr. Carl Barrett steps into a new role as Chief Life Sciences Officer at Corista, a leader in digital image management solutions. This new leadership position, with Dr. Barrett's appointment, continue Corista's commitment to further expansion in the life sciences and biopharma markets, addressing clinical, research, and education sectors.

Key Points: 
  • CONCORD, Mass., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Dr. Carl Barrett steps into a new role as Chief Life Sciences Officer at Corista, a leader in digital image management solutions.
  • His background and experience are perfectly positioned to help us better serve digital image management needs of the medical and life sciences markets," said Corista CEO Liz Wingard.
  • Dr. Barrett brings over three decades of experience in translational research to Corista.
  • Prior to joining Corista, Dr. Barrett was Vice President of Translational Medicine and Oncology Biomarker Development in Oncology Research and Development at AstraZeneca Pharmaceuticals.

Debiopharm Recognizes Pioneering Japanese Cancer Research During the 82nd JCA-Mauvernay Award Ceremony

Retrieved on: 
Tuesday, September 26, 2023

This prestigious award honored remarkable and breakthrough Japanese oncology research in two categories: Innovative and/or Disruptive Research – Dr. Daichi Inoue and Translational Research – Dr. Hiromichi Suzuki.

Key Points: 
  • This prestigious award honored remarkable and breakthrough Japanese oncology research in two categories: Innovative and/or Disruptive Research – Dr. Daichi Inoue and Translational Research – Dr. Hiromichi Suzuki.
  • “We have a strong ambition to support Japanese oncology research in becoming new therapies for cancer patients that need them.
  • This award was inspired by our previous success with the development of oxaliplatin, a standard-of-care now commercialized worldwide to treat metastatic colorectal cancer, pancreatic cancer and liver cancer.
  • Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023

BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • Based on its current plans, Corvus expects its cash to fund operations into the second half of 2024.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the second quarter 2023 financial results.

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

Retrieved on: 
Thursday, June 29, 2023

BURLINGAME, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced new preclinical data for ciforadenant, the Company’s adenosine 2A receptor inhibitor, highlighting its mechanism of action and synergy with immune checkpoint inhibitors via combination with anti-CTLA-4 and anti-PD-1 therapies. The data is being presented in a poster at the 2nd Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference, which is taking place June 28-30, 2023 in Kyoto, Japan.

Key Points: 
  • The data is being presented in a poster at the 2nd Japanese Cancer Association and American Association for Cancer Research (JCA-AACR) Precision Cancer Medicine International Conference, which is taking place June 28-30, 2023 in Kyoto, Japan.
  • “We are exploring this combination in a Phase 1b/2 clinical trial that is being led by the Kidney Cancer Research Consortium.
  • Ciforadenant treatment increased production of chemokine CXCL10, a ligand for recruitment of CXCR3+ Th1 helper cells into the tumor.
  • The combination of ciforadenant with ICB promoted the production of several proinflammatory cytokines such as IL-6, TNFa, and IFNg.

BioAdaptives, Inc. (OTC BDPT) Announces New Appointment to the Board of Directors - Internationally Acclaimed Health Scientist, Author and Patent Holder, Dr. Yaguang Liu

Retrieved on: 
Wednesday, April 5, 2023

LAS VEGAS, NV, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts:  BDPT) announced today the appointment of Dr.Yaguang Liu to its Board of Directors.

Key Points: 
  • LAS VEGAS, NV, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts:  BDPT) announced today the appointment of Dr.Yaguang Liu to its Board of Directors.
  • Edward Jacobs, M.D., CEO Bioadaptives, Inc., states, “We are extremely fortunate to be joined by Dr. Yaguang Liu on our Board of Directors at this time.
  • Dr. Liu brings an extraordinary wealth of research and development experience related to natural medicines and supplements as evidenced by his many important patented discoveries and his impressive leadership activities globally.
  • patents of pure and safe natural botanicals, used for treatment of cancer and cardiovascular and other diseases.

Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023

BERKELEY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the fourth quarter and full year 2022 and reviewed recent pipeline progress.

Key Points: 
  • 3 of 6 patients maintained complete responses at 6 months, with 2 of 6 maintaining complete responses at 12 months.
  • Caribou plans to provide an update from the ongoing ANTLER Phase 1 trial for CB-010 in H2 2023.
  • CB-010: Caribou plans to provide an update from the ongoing ANTLER Phase 1 trial for CB-010 in H2 2023.
  • Caribou expects these cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan into 2025.

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Retrieved on: 
Monday, December 12, 2022

BERKELEY, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced target selection for CB-020, an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 (receptor tyrosine kinase like orphan receptor 1) CAR-NK cell therapy. Preclinical data on the selection of the CB-020 CAR construct and armoring strategies for Caribou’s CAR-NK cell platform will be presented today at the 12th American Association for Cancer Research and Japanese Cancer Association (AACR-JCA) Joint Conference.

Key Points: 
  • “We are leveraging our chRDNA genome-editing technology across our allogeneic CAR-T and CAR-NK cell programs to address disease-specific challenges.
  • ROR1 is a cell signaling receptor that is overexpressed on the surface of several solid tumor types and has been shown to drive tumor cell growth, survival, and metastasis.
  • Multiple armoring strategies are being developed for Caribou’s CAR-NK cell platform to enhance tumor targeting, allogeneic CAR-NK cell survival, and persistence of antitumor activity.
  • “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice

Retrieved on: 
Thursday, December 8, 2022

The American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) are proud to offer this 12th AACR-JCA Joint Conference.

Key Points: 
  • The American Association for Cancer Research (AACR) and Japanese Cancer Association (JCA) are proud to offer this 12th AACR-JCA Joint Conference.
  • Formal and informal interactions as well as international collaborations are fostered through this unique forum.
  • Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer.
  • Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division.

DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY

Retrieved on: 
Monday, October 3, 2022

LAUSANNE, Switzerland , Oct. 3, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Akihide Yoshimi and for Translational Research – Prof. Mamiko Sakata-Yanagimoto. The winners were honored with trophies and a monetary prize during the live event of the 81st Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 1st in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Thierry Mauvernay, President of Debiopharm, and Bertrand Ducrey CEO of Debiopharm. 

Key Points: 
  • "The previous winners of the Mauvernay Award have immediately becomevery well-known scientists in our country, becoming professors and leaders in significant institutes.
  • Therefore, I would say that the Mauvernay Award is definitely a huge step for young cancer research scientists in our country."
  • Dr. Akihide Yoshimi's disruptive research at the National Cancer Center Research Institute, is aimed at understanding and targeting aberrant RNA splicing inhematological malignancies.
  • Since 2005, the Japanese Cancer Association (JCA) and Debiopharm have co-organized the 'JCA-Mauvernay Award'.